팝업레이어 알림

팝업레이어 알림이 없습니다.

Create health, happy lives and beautiful future

EDGC is at the center of the revolution beginning to disappear a border between industries as technologies converge.

  • Help to maintain healthy pregnancy by analyzing fetal chromosomal abnormalities.
  • Detect chromosomal abnormalities a baby may have.
  • Parents can take care of children’s health with proper treatment of analyzing their genes.
  • Analyze the genetic risk of diseases to help prevent them in advance.

Genetic Analysis Service Throughout the Life Cycle

  • What does
    your DNA look like?

    MIT Technology Review paid attention to
    ‘Genetic Fortune Telling’ in ’10 Breakthrough Technologies 2018’.
    Genes have all the information you may wish to know.
    Your genes exactly know your weaknesses, personality, aptitude and even the most effective exercises for you.
    Start to prepare for the era of the healthy 100-year life through genetic analysis.

  • EDGC is
    a global healthcare
    company.

    EDGC analyzes your genes based on
    cutting-edge genetic analysis technology and bioinformatics technology and suggests personalized lifestyle to help prevent diseases.

Business

EDGC Service

  • Non-Invasive Prenatal Test

    NICE®

    NICE® test, which has been verified its accuracy and reliability by acquiring CLIA and CAP certificates, detects fetal chromosomal abnormalities safely and easily.

  • Newborn Genetic Screening Test

    bebegene®

    bebegene® which detects chromosomal abnormalities such as major genetic diseases, Wilson’s Disease, ADHD, hearing loss and so on is the first test for a precious baby.

  • Integrated Genotype and Phenotype Test

    MYGENPLAN®

    MYGENPLAN® is the first integrated test in South Korea which analyzes metabolic genes and biological age and suggests personalized healthcare guide.

  • Cancer and General Disease Prediction Test

    gene2me® Plus

    gene2me® Plus predicts the genetic risk of major cancer, general diseases and eye diseases, and designs healthy future with early personalized treatment.

Recent News

EDGC Recent News

Article

 [EDGC liquid biopsy ‘ONCOCATCH-CDxTM logo / photo provided by EDGC]Eone-Diagnomics Genome Center(EDGC) has established a bridgehead to preoccupy the European market for next-generation precision medical innovation technology liquid biopsy and secure personalized chemotheraphy big data.  EDGC announced on 15th that it has signed corporate marketing agreement with Molecular Health(MH), German biotechnology IT company, for liquid biopsy ‘ONCOCATCH-CDxTM which is an early cancer diagnosis technology. ONCOCATCH-CDx is leading-edge technology that analyzes cancer cell-derived ctDNA which is released from circulating tumor DNA (cell free DNA) in trace amount. This can be applied in all stage of cancer diagnosis and treatment based on early diagnosis of cancer, monitoring of cancer metastasis and recurrence and companion diagnostics for personalized anticancer therapy.Especially, ONCOCATCH-CDx provide early diagnosis and tumor location of 10 major cancers such as colorectal cancer, lung cancer, breast cancer and stomach cancer through Methylation analysis with acquired somatic cell mutation that causes cancer and the specific pattern of tissue/cancer. Only Illumina(GRAIL) in the U.S and EDGC have such the highest level of technology development in the world. For this reason, GenomeWeb, a global life science journal, reported that ONCOCATCH-CDx is the world’s best advanced technology for early cancer diagnosis. EDGC liquid biopsy companion diagnosis service provides high-quality service for doctors and patients to make a decision about proper treatment by utilizing MH’s database platform ‘DATAOME’  which matches each patient’s personalized medicine prescription ingredients and quantity for about 28,000 genetic mutations Based on this, not only corporate marketing of liquid biopsy ONCOCATCH-CDx, but also developing a program that will be helped medical team to prescribe personal anticancer drugs.    “The co​operation between the two companies will greatly improve the diagnosis and personalized treatment of cancer in the precision medicine field.” said Stephan Hettich who is Senior Vice President of MH “We are very happy to enter and expand the Asian Market with EDGC.” Jeong Yoo-seok, EDGC Global Business Department Team Leader, said that “When combining MH Guide, including 28.000 gene variant – drug relations, with EDGC’s companion diagnostics service ONCOCATCH-CDx is possible to prescribe personalized chemotheraphy for each patient. “We are looking forward to our partnership with Molecular Health to further establish our leading positions in the upcoming precision medicine market for liquid biopsy”, he adds.In addition, MH is headquartered in Heidelberg, Germany, and provide service to government agency, hospital, pharmaceutical, and bio company in more than 30 countries including Europe and the United States.

2021.09.15

Global Network

EONE-DIAGNOMICS GENOME CENTER

EDGC Promotion Video

No posts found.